ISIN | LU2353392348 |
---|---|
Valor Number | 112071796 |
Bloomberg Global ID | |
Fund Name | Pictet-Biotech HR AUD |
Fund Provider |
Pictet Asset Management S.A.
Genève, Switzerland Phone: +41 58 323 10 24 www.assetmanagement.pictet |
Fund Provider | Pictet Asset Management S.A. |
Representative in Switzerland |
Pictet Asset Management S.A. Genève 73 Phone: +41 58 323 30 00 |
Distributor(s) |
Credit Suisse AG Zürich Phone: +41 44 333 11 11 UBS AG Zürich Phone: +41 44 234 11 11 Vontobel Fonds Services AG Zürich Phone: +41 58 283 74 77 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs. |
Peculiarities |
Current Price * | 643.51 AUD | 03.04.2025 |
---|---|---|
Previous Price * | 638.46 AUD | 02.04.2025 |
52 Week High * | 853.66 AUD | 16.07.2024 |
52 Week Low * | 638.46 AUD | 02.04.2025 |
NAV * | 643.51 AUD | 03.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,930,791,088 | |
Unit/Share Assets *** | 346,444 | |
Trading Information SIX |
YTD Performance | -11.01% |
31.12.2024 - 03.04.2025
31.12.2024 03.04.2025 |
---|---|---|
YTD Performance (in CHF) | -12.56% |
31.12.2024 - 03.04.2025
31.12.2024 03.04.2025 |
1 month | -11.01% |
03.03.2025 - 03.04.2025
03.03.2025 03.04.2025 |
3 months | -12.58% |
03.01.2025 - 03.04.2025
03.01.2025 03.04.2025 |
6 months | -17.97% |
03.10.2024 - 03.04.2025
03.10.2024 03.04.2025 |
1 year | -14.42% |
04.04.2024 - 03.04.2025
04.04.2024 03.04.2025 |
2 years | -1.31% |
03.04.2023 - 03.04.2025
03.04.2023 03.04.2025 |
3 years | -7.96% |
04.04.2022 - 03.04.2025
04.04.2022 03.04.2025 |
5 years | -28.68% |
22.06.2021 - 03.04.2025
22.06.2021 03.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Gilead Sciences Inc | 6.57% | |
---|---|---|
Insmed Inc | 5.17% | |
argenx SE ADR | 4.87% | |
Regeneron Pharmaceuticals Inc | 3.55% | |
SpringWorks Therapeutics Inc Ordinary Shares | 3.08% | |
Sarepta Therapeutics Inc | 3.07% | |
Alnylam Pharmaceuticals Inc | 3.03% | |
Amgen Inc | 2.94% | |
TG Therapeutics Inc | 2.86% | |
Vaxcyte Inc Ordinary Shares | 2.83% | |
Last data update | 28.02.2025 |
TER *** | 2.75% |
---|---|
TER date *** | 30.09.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.90% |
Ongoing Charges *** | 2.75% |
SRRI ***
|
|
SRRI date *** | 31.07.2021 |